International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. - Wikidata - wikimedia - TriplyDB

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

http://www.wikidata.org/entity/Q33404714

about

The evolution of anticoagulant therapy Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art Venous thromboembolism in cancer patients: an underestimated major health problem Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion.Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report.Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux Venous thromboembolic prophylaxis after a hepatic resection: patterns of care among liver surgeons.Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study.Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia.The Treatment of Venous Thromboembolism in Patients with Cancer.Controversies in the management of cancer-associated thrombosis.Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort.Acupuncture safety in patients receiving anticoagulants: a systematic review.Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Inferior vena cava filters: current best practices.Implementing thrombosis guidelines in cancer patients: a review.Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Decision-making in a patient with cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection.Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial.Postoperative Massive Pulmonary Embolism Due to Superficial Vein Thrombosis of the Upper Limb Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer.Impact of a dedicated cancer-associated thrombosis service on clinical outcomes: a mixed-methods evaluation of a clinical improvement exercise.New oral anticoagulants and the cancer patient.Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism.Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients.Venous thromboembolism in children with cancer - a population-based cohort study.Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study

P2860

Q26771859-C588AB41-9465-42D2-B1F4-C5433D2D6863 Q26776112-3E3614C9-4658-4471-8EF7-EF340C304FE8 Q26852015-BA3823B8-F127-4DD3-91B2-254FC8D6B52F Q30590837-0C32535F-34E0-4CE7-A111-B48D5F54FBEA Q33166582-DB9356E3-3248-4A99-B7EB-8340FA7FE803 Q33410578-C6FBD2C5-5A8C-4306-9910-B620B084B2BB Q33415676-9E377435-0EFC-4EEF-9DAF-0AC87B3B4F05 Q33416407-B532CB69-E842-4381-8295-DD67D61CF309 Q33417504-2B371005-0970-4C92-BB8B-9B3C84090127 Q33429840-1FCD4BBC-880F-4F5C-AEE1-04EC2C640C73 Q33434346-CCA996FC-C1CD-4FB4-8DAB-179B5EB9C5E2 Q33435329-1976B87C-088F-4437-8487-E4F7EB35B7A4 Q33436975-03A47B6F-6F31-48DF-9BBD-6A91037D67C7 Q33440816-039AA89A-2FB3-4ED1-A6F3-777922FEB017 Q33686796-B4DF06F1-B879-46E4-A85F-28A6FF1131EA Q33735646-D759F28C-BB29-4E1A-92FA-B0841C6916F3 Q34436061-E6AA1464-AAAF-4F5F-8176-B4F988E417A8 Q34462703-719B005A-0B06-4E42-A0E5-C971E2847815 Q34463482-EB3BF286-52F3-40EA-BE0E-D09B8D1FD2B2 Q34721483-D0AAB715-B2BB-420D-8C76-A1AB74F1BCC6 Q34893956-2710FBA6-FAEC-4D6E-A26D-12D3626B1FE7 Q35142746-82BFE3EA-E954-408E-8F6D-BAE31072146B Q35174604-ADDD1EF0-17F8-4908-A511-6136E2714FC1 Q35683869-286D7450-0AC9-4BE4-8325-B0AF39C26AD9 Q36163379-446155B2-866D-4D9D-8AD0-219F076FCF91 Q36195033-A9C8044A-2EEA-45F7-B48E-F4335355EA56 Q36281232-64FE755E-FD16-46E2-9E54-1BC991464FDD Q36658562-7C86C901-AF3D-4E95-A895-A962A3A4CF65 Q36779739-876D4C12-9762-4B6C-9136-3E1FA9CB6751 Q36839479-01AC766F-355E-4F01-8EE1-252C64A59799 Q37152911-BC2C78DD-BADD-4CEA-A2D1-B5879598CC3E Q37216645-E6E1EDC8-84B5-43B8-AA3A-C00C49BB741E Q37304305-7C6C9909-D2A9-4BCC-98A9-715BE17D31DA Q37516663-7CC8EAB4-91B9-4DAD-951E-40C2F78CD805 Q37519054-D34C54DE-7BD2-41D2-81C6-217167552B4C Q37587205-A0E09D24-7264-4B2A-ACE7-6EC22EA5D7D0 Q37588677-1C3AD815-442C-41A8-BF52-DA6BD6643B7E Q37669093-CCC736B5-A513-42A3-BD02-1CB6F47671E7 Q37672276-EF029E60-BF23-411C-ADCC-20804B9687A4 Q37702182-E7ED0885-7B4C-4782-B49F-D297858AD284

P2860

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

http://www.wikidata.org/entity/Q33404714

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

International clinical practic ...... olism in patients with cancer.

@ast

International clinical practic ...... olism in patients with cancer.

@en

type

label

International clinical practic ...... olism in patients with cancer.

@ast

International clinical practic ...... olism in patients with cancer.

@en

prefLabel

International clinical practic ...... olism in patients with cancer.

@ast

International clinical practic ...... olism in patients with cancer.

@en

P1433

Q33404714-9635DF41-296F-4719-B9CC-4B18C3167CBF

P1476

Q33404714-AF929D7E-F27C-451C-82F8-1193459C03FB

P2093

Q33404714-051873A6-3CD3-44A1-8A43-0CAAF7D1C4AD

Q33404714-0F6CED5A-7707-415C-B924-F471C4EE6887

Q33404714-136F2CF7-AB1E-473A-9727-A9D26C8D08F7

Q33404714-1D278BAE-3188-4691-9C26-04B16C17A9F8

Q33404714-200B5BEB-9DD8-4152-8101-9A44770E0839

Q33404714-2E57FD38-9516-4B9A-8316-39BDE4FEF328

Q33404714-350219CF-7E4E-41B7-8C7D-79B1145BC204

Q33404714-3865DD9D-D2DA-4767-B6EB-7522B812F600

Q33404714-5CB8DDF7-114D-4CED-88F8-C5D30182F1A7

Q33404714-5F7DEA6A-D9EA-4896-8A0D-D635B0BBC5A1

P304

Q33404714-09EF44C8-DEDE-4F4B-B6BA-AA81E1D9CD17

P31

Q33404714-64712a21-81ab-473f-b20a-a36f2dd0806f

Q33404714-CACD3BF8-A40A-4754-98F0-7E2782A91607

P356

Q33404714-405354FA-8D7A-4324-B552-B938A1DC72EC

P433

Q33404714-0286FF9E-69DB-470C-96DF-2431A01757DE

P478

Q33404714-04C6FF19-CBD4-4154-B07E-CD2D75FD254A

P50

Q33404714-A5890543-2BDC-4435-9A24-22C3240E7809

Q33404714-B1F0414D-117E-4072-B1B2-6EA94DA12BF0

Q33404714-B8D82893-3E93-458E-9846-93982E8D6818

Q33404714-DE6242F9-02F4-4AFA-99D4-DBD48BCA5133

Q33404714-F375605B-E77D-4F93-B29F-D4A48D3BF297

P577

Q33404714-AF312705-CB95-4246-A9AB-27A419DFB33F

P5875

Q33404714-DEF8CF3C-8A74-4FAB-85B5-92096EB18C94

P698

Q33404714-D40C357A-EA93-4C3E-9DBF-40DBD9EDE70D

P921

Q33404714-4CB665E3-313E-4C85-B035-F973993F58F3

Q33404714-CCAF6C11-BE91-4B39-AD4A-5B4ED76707B1

P356

P1433

Journal of Thrombosis and Haemostasis

P1476

International clinical practic ...... bolism in patients with cancer

@en

P2093

A K Kakkar

http://www.w3.org/2001/XMLSchema#string

B Brenner

http://www.w3.org/2001/XMLSchema#string

C Baglin

http://www.w3.org/2001/XMLSchema#string

D Brilhante

http://www.w3.org/2001/XMLSchema#string

D Farge

http://www.w3.org/2001/XMLSchema#string

G T Gerotzafias

http://www.w3.org/2001/XMLSchema#string

H Bounameaux

http://www.w3.org/2001/XMLSchema#string

H R Büller

http://www.w3.org/2001/XMLSchema#string

I Pabinger

http://www.w3.org/2001/XMLSchema#string

K Syrigos

http://www.w3.org/2001/XMLSchema#string

P304

56-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JTH.12070

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Debourdeau

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233875232

http://www.w3.org/2001/XMLSchema#string

P698

23217107

http://www.w3.org/2001/XMLSchema#string

P921

venous thromboembolism